AZ drops IL-23 drug for inflammatory bowel disease

AstraZeneca has taken a look at the competition emerging in the market for inflammatory bowel disease (IBD) therapies, and decided to shelve a project that had advanced in

AbbVie/Allergan merger cleared in EU with brazikumab sell-of...

AbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of pipeline gastrointestinal autoimmune diseases drug brazikumab to AstraZen

Allergan says it will shed two drugs as AbbVie takeover loom...